The Framework Explained

The painkiller-vitamin distinction is a mental model for classifying how urgently a product or service addresses a customer's need.

A painkiller solves a problem the customer is actively experiencing and motivated to fix. The pain exists now. The customer is already looking for a solution, already spending money or time on workarounds, and would pay immediately if you could make the pain stop. The decision to buy is driven by necessity.

A vitamin addresses a problem the customer acknowledges exists but is not currently acting on. The customer might agree that your product is useful, even interesting. But they are not searching for a solution, not spending on workarounds, and not experiencing urgency. The decision to buy — if it happens — is driven by aspiration or convenience, not necessity.

Most consumer and enterprise products exist on a spectrum between these two poles. The goal of this framework is not to produce a binary classification but to be honest about where on the spectrum your product sits, and to understand what that means for your go-to-market, your pricing, and your fundability.

Investors in the GCC, as elsewhere, overwhelmingly prefer painkiller companies. Not because vitamins cannot build businesses — they can — but because the sales cycle is shorter, the switching cost is lower, and the urgency is self-evident. A painkiller sells itself. A vitamin requires sustained marketing and education, which is expensive and slow.

Questions That Reveal Urgency

The best diagnostic for where your solution sits on the spectrum is a set of customer discovery questions designed to surface urgency rather than interest.

Interest is the wrong signal. Almost everyone is "interested" in a product that could make their life or work slightly better. Interest does not predict purchase. Urgency does.

The questions that reveal urgency — adapted from the Mom Test methodology — focus on recent behaviour, not hypothetical intent:

"Tell me about the last time you dealt with this problem." If the customer cannot remember a specific instance, the problem may not be acute enough to generate painkiller-level demand. If they tell you a detailed, emotionally charged story, urgency is present.

"What have you done to solve it?" This is one of the most diagnostic questions in customer discovery. If the customer has not done anything — has not searched for a solution, has not tried a workaround, has not asked their network — the problem is not painful enough. If they have built a spreadsheet, hired someone, or paid for a partial solution, you have a painkiller context.

"How much did you spend / how much time did you lose because of this problem in the last month?" Putting a cost estimate on the problem forces the customer to connect the issue to money. If they cannot estimate a cost, the problem likely does not rise to painkiller status. If they can — and especially if the cost surprises them when they say it out loud — you have a strong urgency signal.

"If I could solve this for you right now, what would you pay per month?" Hypothetical pricing questions are unreliable, but they are useful as a directional signal. A customer who says "nothing" or "as little as possible" is telling you something important about perceived urgency. A customer who names a specific number without hesitation is closer to painkiller territory.

Willingness-to-Pay as the Truth Test

All of the qualitative signals above are useful, but they are not the truth test. The truth test is willingness to pay, demonstrated through actual payment behaviour — not hypothetical answers to hypothetical questions.

The most effective early-stage willingness-to-pay experiment is pre-sales. Before building, offer your solution — even in a manual, concierge form — for a price. The price does not need to be your long-term pricing. It just needs to be a real number that the customer must commit to paying.

If they pay, you have painkiller evidence. If they agree it is a great idea but do not pay, you have vitamin evidence. The distinction is stark and reliable in a way that no survey or interview can replicate.

A second effective test is the letter of intent (LOI). In B2B contexts — particularly in the UAE and Saudi Arabia, where enterprise sales cycles are long — an LOI is a signed document in which a prospective customer commits to purchasing or piloting the product when it is ready, often with a defined price. An LOI is not a contract and is not legally binding in most cases, but the act of signing one filters out politely interested contacts from genuinely motivated buyers.

A third test is deposit-based waitlists. Rather than simply asking people to join a waitlist (which is easy and therefore produces low-quality signal), ask them to put down a small, refundable deposit — AED 100 or AED 500 — to reserve their spot. The conversion rate from free waitlist to depositing waitlist is one of the clearest urgency tests available.

GCC Examples Across Sectors

The painkiller-vitamin distinction plays out differently across GCC sectors. Here are several illustrative patterns.

B2B compliance and payroll tools (UAE, KSA): These are almost always painkillers. Non-compliance with Saudization quotas, WPS requirements, or GOSI contributions has direct financial and legal consequences. Companies are paying for solutions or workarounds today. A founder entering this space is solving a problem customers are already spending on, which is the clearest painkiller signal available.

Employee wellness apps: Almost always vitamins. HR managers may express genuine enthusiasm for the idea. They may agree that employee mental health is important. But when asked what they have spent on solving it in the last quarter, the answer is typically nothing or minimal. The urgency is intellectual, not operational.

SMB accounting and bookkeeping tools (UAE): Often a painkiller at tax time, a vitamin in between. Many UAE SMBs manage their accounting manually or through their accountant and experience acute pain at year-end or during VAT filing. A tool that positions itself as reducing the year-end pain — rather than as a general productivity improvement — lands as a painkiller.

AI-powered customer service tools for e-commerce: Can be either, depending on scale. For a business doing thirty customer enquiries per day, this is a vitamin. For a business doing three hundred, the manual overhead is a real operational cost. The positioning of the product needs to match the urgency threshold of the target segment.

Repositioning a Vitamin Into a Painkiller

If your solution is currently a vitamin, this does not necessarily mean your business is unviable. It may mean that your positioning, your target customer, or your entry point needs adjustment.

The most common repositioning move is to find the sub-segment of your market where the problem is most acute. A general productivity tool for professionals is a vitamin. The same tool positioned specifically for the workflow that causes the most daily friction for a specific type of professional — accountants during reporting season, recruiters during bulk hiring cycles — may operate as a painkiller for that segment.

A second move is to find the triggering moment — the specific event that turns a chronic, tolerable problem into an urgent one. For cybersecurity tools, the trigger is often a near-miss incident or a compliance audit. For HR tools in KSA, the trigger is often a Nitaqat (Saudization) audit or a new hire cycle that reveals compliance gaps. If you can position your product to show up at that triggering moment, you can command painkiller-level urgency from customers who would otherwise be vitamins.

A third move is to add a regulatory or financial consequence layer. Many founders building in GCC markets underestimate the urgency-generating power of compliance requirements. If your tool helps businesses avoid a fine, stay compliant with a regulation, or qualify for a government contract, the problem becomes a painkiller by definition. Look for the regulatory hook.

FAQ

Q: Can a vitamin become a painkiller over time? Yes, but this typically requires a change in the market, not in the product. Market conditions that turn vitamins into painkillers include new regulations (a compliance requirement is suddenly attached to a previously optional behaviour), industry disruption (a competitor move makes your category urgent), or a cultural shift that raises urgency. Building a vitamin and waiting for the market to develop is a viable strategy — but it requires enough runway to outlast the wait.

Q: Is it okay to launch a vitamin if it has strong unit economics? Yes, with caveats. Vitamins can be excellent businesses — the consumer wellness, subscription media, and productivity tool markets are evidence of this. But they require sustained acquisition spend, strong content marketing, and long sales cycles. In the GCC, where capital efficiency is a priority and the investor market is selective, vitamins face a higher bar to fundability than painkillers.

Q: How many willingness-to-pay tests do I need before I have a painkiller signal? In B2B contexts, three to five paying customers or signed LOIs is a meaningful early signal. In B2C contexts, the bar is higher — you need a larger sample because individual purchase amounts are smaller and the noise is higher. A general rule: if you have ten customers who paid for your product at a price that suggests you can build a real business, and none of them required significant discounting or special persuasion, you have a painkiller signal.

Q: My interviewees say it is urgent but will not pay. What does that mean? It usually means one of three things: the urgency is real but the solution is not compelling, the price is wrong, or the stated urgency is polite inflation rather than genuine urgency. The diagnostic is to make the ask more concrete. Instead of "would you pay for this?" try "I can deliver this for you manually starting next week for AED 300 per month. Want to get started?" The response to a real, time-bound, priced offer tells you what you need to know.

Q: Does the vitamin-painkiller distinction apply to B2G (business-to-government) sales in the GCC? It applies differently. Government buyers in the GCC are often motivated by mandate rather than urgency — they are required to procure a solution, not seeking one because they feel pain. This makes B2G both easier (the purchase decision is less discretionary) and harder (the procurement process is longer and more political). The useful framing for B2G is not "does this solve an urgent problem" but "does this fulfill a requirement or advance a mandate."

Conclusion

The vitamin-painkiller framework is not a judgment on your idea. It is a diagnostic that tells you where you are in the urgency spectrum, what that means for your go-to-market, and where the gaps in your validation evidence are.

The founders who waste the most time and capital are those who build vitamins while believing they have painkillers — and who discover the difference only at launch. The questions and tests in this article, run before you build, will tell you the truth before the market does.

If you find out you have a vitamin, that is useful information. Reposition, find the urgency hook, or consciously build a vitamin business with the right economics and expectations. Just do not build a vitamin while pretending it is a painkiller.

Vitamin or Painkiller? How to Test Whether Your Solution Is a Must-Have